Nelson Dusetti: Identifying resistant pancreatic adenocarcinoma phenotypes with ‘PANCprofiler’
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:
“On Saturday, March 22, at 16:20, Paris Congress Centre session C.159 at JFHODs!
We’ll be discussing how a deconvolution approach, applied to the PRODIGE24 clinical cohort, helps predict patient response to chemotherapy (mFOLFIRINOX and gemcitabine) by mapping intra-tumor heterogeneity.
We will be showcasing ‘PANCprofiler,’ a stratification algorithm designed to identify resistant pancreatic adenocarcinoma phenotypes at single cell level. This project is part of the PRODIGE24/Mosapac consortium.
We look forward to seeing you and sharing perspectives on advancing personalized medicine for pancreatic cancer!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023